Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
Phase 2
- Conditions
- Liver Neoplasms
- Interventions
- Procedure: Targeted Cryoablation Therapy
- Registration Number
- NCT02969096
- Lead Sponsor
- Shanghai University of Traditional Chinese Medicine
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of targeted cryoablation therapy for hepatic carcinoma.
- Detailed Description
A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 10-6-10minutes.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Diagnosis of liver cancer based on histology or the current accepted radiological measures.
- Single Tumor size ≤5.0 cm in greatest diameter, or multiple tumor number≤3 and each tumor size≤ 3cm.
- Life expectancy: Greater than 3 months.
- Patients' liver function is Child-pugh A or B.
- Ability to understand the study protocol and a willingness to sign a written informed consent document.
- Unable to receive operative surgery.
Exclusion Criteria
- Patients with other primary tumor except liver cancer.
- History of coagulation disorders or anemia.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Targeted Cryoablation Therapy Targeted Cryoablation Therapy liver cancer patients received targeted cryoablation therapy.
- Primary Outcome Measures
Name Time Method Rate of complete tumor ablation Up to 4 weeks post surgery
- Secondary Outcome Measures
Name Time Method Adverse Events Up to 4 weeks post surgery
Trial Locations
- Locations (1)
Shanghai Longhua Hospital
🇨🇳Shanghai, Shanghai, China